Objective To explore the clinical effect of dapagliflozin+repaglinide+insulin glargine in patients with type 2 diabetes mellitus.Methods A total of 120 patients with type 2 diabetes mellitus admitted to Tengzhou Dongshahe Community Health Service Center from March 2020 to November 2023 were selected as the research objects.Accord-ing to different treatment methods,they were divided into reference group and study group,with 60 cases in each group.The reference group was treated with repaglinide combined with insulin glargine,and the study group was treated with dapagliflozin on the basis of the reference group.The total effective rate,islet function level(islet β cell function index,insulin resistance index),blood glucose level(fasting blood glucose,glycated hemoglobin A1c,2-hour postprandial blood glucose)and total incidence of adverse reactions were compared between the two groups.Results The total effective rate of the study group was higher than that of the reference group,and the difference was statisti-cally significant(P<0.05).The islet β cell function index of the study group was higher than that of the reference group,and the insulin resistance index,fasting blood glucose,glycated hemoglobin A1c and 2-hour postprandial blood glucose levels were lower than those of the reference group,and the differences were statistically significant(all P<0.05).There was no statistically significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion The application of dapagliflozin+repaglinide+insulin glargine in the treatment of type 2 diabetes mellitus has obvious clinical effect,which can effectively reduce the level of blood glucose indicators and im-prove islet function.
维普
万方数据
